Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Share :
Published: 2 Jun 2014
Views: 3251
Dr Enrique Grande - Hospital Ramon y Cajal, Madrid, Spain

Dr Grande talks to ecancertv at ASCO 2014 about his work looking at regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer. The work is ongoing but has indicated that the drug is safe and potentially beneficial in those who are too frail to undergo chemotherapy.